Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Health: Protein gut check
Toggle Summary Former Merck dealmaker takes aim at colon germ
n">An infectious disease expert and former head dealmaker at Merck & Co is racing against his ex-employer and other drugmakers to develop a treatment for a germ that ravages the colon and kills as many as 14,000 Americans each year. Roger Pomerantz on Monday became chief executive officer of
Toggle Summary Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman
CAMBRIDGE, Mass. , June 2, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has appointed Roger J. Pomerantz , M.D., F.A.C.P.
Toggle Summary Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass. , March 25, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, today announced that CEO and Co-founder Dr.
Toggle Summary Human Microbiome Therapeutics named a Top 10 emerging technologies for 2014
Toggle Summary Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile
Clinical efficacy observed in first 10 patients CAMBRIDGE, Mass. , Jan. 13, 2014 /PRNewswire/ -- Seres Health today announced interim results from a single-arm, open-label clinical trial evaluating its lead Ecobiotic™ candidate, SER-109, a microbial therapeutic developed for the treatment of
Toggle Summary A Pill Filled with Bacteria Instead of Drugs
Delivering healthy bacteria in a pill could help patients harboring out-of-balance microbial communities. Yogurt eaters already know that not all bacteria are bad for you. They may not realize that some bacteria are so important that one day people may   fight off disease with pills filled with
Toggle Summary Bugs in the clinic
Toggle Summary Flagship Takes a Stab at Microbiome Therapy With Seres Health
We live every day with trillions of bacterial neighbors that do all sorts of mysterious things in our guts, good and bad. The broadening scientific understanding of the “ microbiome ,” powered by the modern tools of genomic analysis, has been in the news for a while.
Toggle Summary Flagship VentureLabs™ Introduces Seres Health - Early Leader in the Development of Novel Therapeutics to Treat Diseases of the Human Microbiome
CAMBRIDGE, Mass. , Nov. 21, 2013 /PRNewswire/ -- Flagship VentureLabs announced today the launch of Seres Health after two years of development in stealth mode and $10.5 million in Series A financing during that period from Flagship Ventures and other investors.  Seres Health is a clinical-stage

Back to top